Given the significance of GR activity in ENZ-resistant PCa cells [1, 7] and the positive association between EP300 chromatin occupancy in lung cancer cells and GR binding [30], EP300/CREBBP inhibitors could potentially counteract the GR-mediated replacement of AR signaling. This evidence concerns the gene NR3C1 and lung cancer.